Aug 5, 2026 earnings call — EPS guidance raised after specialty-driven quarter
Cencora raised fiscal 2026 adjusted EPS guidance to $17.75 to $17.95 after Q3 results and $1 billion in opportunistic share repurchases.
Revenue $84.8B (est $84.3B) · EPS $4.48 (est $4.35)
Key quotes
"First, our differentiated specialty pharmaceutical platform uniquely positions us to support innovation and patient care across our footprint."
"A tangible example of this is our work in demand forecasting. Our teams are using AI to better anticipate product needs across our network and identify key factors driving changes in demand."
"Next, through our focus on talent culture, we're equipping our teams to continue advancing our pharmaceutical-centric strategy and delivering on our purpose."
Analyst Q&A 12
U.S. pharma growth and 2027 outlook
Q (Lisa Gill · JPMorgan): Analyst asked if the U.S. pharma growth this quarter is a true reacceleration versus last quarter and whether the Street's ~14% fiscal 2027 growth expectation is within management's range.
A: Management said the outperformance was largely in the U.S., driven by MSOs and specialty strength across health systems and physician providers, and excluding the Florida Cancer loss and OneOncology the operating income growth was up double digits versus 7% last quarter. On 2027, management provided modeling guidance but would not add beyond that, and reiterated confidence in the long-term guidance and the portfolio to keep results within that range.
"On the outperformance, it was largely in the U.S. segment, with strength in our MSOs and underlying business trends in the core with strength in specialty in both health systems as well as physician providers." — Eva Boratto (CFO)
Biosimilars impact on Part B vs Part D
Q (Glen Santangelo · Barclays): Analyst asked for more color on the specialty strength and to separate the effects in Part D versus Part B, expecting Part B to be the bigger driver.
A: Management said biosimilars are good for patients, cost, and access. They noted biosimilars are only incrementally positive in Part D because Cencora provides fewer wraparound services there and may see revenue decreases when customers insource, while Part B (buy-and-bill infusion) is more important because MSOs, distribution and GPOs provide more services and a larger profit opportunity.
"And that is because the Part B buy-and-bill infusion space, which is where our MSOs where our distribution and GPOs have such a long history of supporting physicians." — Robert Mauch (CEO)
OneOncology integration and sustainability
Q (Elizabeth Anderson · Evercore): Analyst asked what operational improvements are visible in OneOncology, how far along integration efforts are, and whether above-average growth is sustainable.
A: Management described a three-phase value-creation plan: integration (significant progress on RCA, good progress on OneOncology), sharing capabilities across platforms (early days), and developing new services later, all supported by adding physicians. They also said OneOncology is expected to be neutral on adjusted EPS net of financing over a 12-month basis, and an accounting change around UUG noncontrolling interest had no impact to operating income with operating income modestly better than initial expectations.
"As you think about it on a 12-month basis, we continue to expect OneOncology to be neutral from an adjusted earnings per share net of financing." — Eva Boratto (CFO)
Q2–Q3 rebound drivers and 340B
Q (Allen Lutz · BofA): Analyst asked whether the sequential rebound was due to one-time calendar effects (e.g., IRA) or other dynamics, and whether recent changes in 340B affect the business.
A: Management said the acceleration from Q2 to Q3 was driven by underlying utilization strength and that Q4 guidance implies strong double-digit growth with OneOncology lapped out and an easier expense comparison; excluding OneOncology they expect the strongest organic growth of the year at the midpoint. On 340B, management said they are still assessing recent guidance, will continue to monitor and engage with regulators and legislators, and their focus is patient access and efficient care.
"So we will participate in continuing to monitor, talking to regulators and legislators about potential unintended consequences." — Robert Mauch (CEO)
Clinical trials role and maturity in MSOs
Q (Charles Rhyee · TD Cowen): Analyst asked how much clinical trial and research activity OneOncology already does, how material it is to revenue or profit today, and how mature that opportunity is.
A: Management said clinical trials are an absolute driver of profitability and growth across the MSOs; RCA is mature in clinical trials with a well-respected platform in retina, while OneOncology has meaningful activity but is in earlier innings with significant opportunity for growth. They also emphasized that community-based clinical trial access helps patient access and trial accrual for manufacturers.
"So one, as we expand the clinical trial business within the MSOs, it's an absolute driver of profitability and growth." — Robert Mauch (CEO)
3PL competitiveness and oncology trends
Q (George Hill · Deutsche Bank): Analyst asked about increased competition in 3PL/World Courier over the past 12 months and whether any oncology market slowdown is affecting Q4 guidance.
A: Management said they are well positioned in specialty logistics and 3PL, with differentiated, pharma-focused capabilities (World Courier and ICS) that allow them to compete at the high end despite credible competitors. They also said specialty including oncology showed good utilization and consistent growth in Q3, and Q4 guidance implies a sequential improvement with U.S. showing strongest organic growth at the midpoint.
"We play at a higher end of those services and also find that the pharmaceutical manufacturers often prefer someone who is a health pharmaceutical focused." — Robert Mauch (CEO)
ASP rule changes and reimbursement risk
Q (Kevin Caliendo · UBS): Analyst asked how proposed ASP rule changes might change ASPs and affect MSO or GPO businesses and whether they can quantify the risk.
A: Management said they study policy ideas and believe the policies under consideration are not intended to impact physician reimbursement, emphasizing patient access and cost effectiveness. They cited the GLOBE demonstration approach where manufacturer discounts to government would be direct payments and not flow through reimbursement, and said they feel confident reimbursement to physicians will not be negatively impacted as this plays out toward 2028 with IRA and Part B.
"but we do feel confident that as this plays out and as we get to 2028, in particular with IRA and Part B that the reimbursement to physicians will not be negatively impacted." — Robert Mauch (CEO)
MSO investment focus and capital plans
Q (Erin Wilson Wright · Morgan Stanley): Analyst asked if management will invest more in MSOs given regulatory dynamics and biosimilar opportunities, and asked Eva about any surprises since joining and her philosophy on guidance and capital deployment.
A: Management said they remain confident in the community physician space and will continue to invest in MSOs, focusing on tuck-in acquisitions in retina (RCA) and oncology (OneOncology) and not expanding MSOs into other ologies now. Eva said she sets disciplined guidance based on internal processes, plans to continue Cencora's capital allocation approach, and that capital deployment priorities are internal investments, strategic M&A, opportunistic share repurchase, and maintaining a reasonable and growing dividend.
"our capital deployment strategy remains focused on internal investments in the business, strategic M&A, opportunistic share repurchase, as we just did in the third fiscal quarter and maintaining a reasonable and growing dividend." — Eva Boratto (CFO)
Held-for-sale benefit and GLP-1 sales
Q (Eric Coldwell · Baird): Analyst asked to quantify the held-for-sale accounting benefit in the Other segment, and asked how GLP-1 sales compared to expectations and about the GLP-1 Bridge program with Medicare.
A: Management said the majority of growth in the Other segment was driven by held-for-sale accounting, and that underlying MWI delivered about 10% growth which drove the change to their outlook for the year. For GLP-1s, management said sales were up 25% and that was generally in line with expectations.
"Underlying MWI delivered about 10% growth and drove the change to our outlook for the year." — Eva Boratto (CFO)
Drivers of European distribution growth
Q (Daniel Grosslight · Citi): Analyst asked which geographies or therapeutic categories are driving European distribution growth, whether it is broad-based or concentrated, and any issues to watch entering fiscal 2027 besides tougher comps.
A: Management said European distribution benefited from timing of manufacturer price increases in developing market country, but they would not expect that same impact in Q4 because of timing. They added specialty logistics (World Courier and European 3PL) delivered double-digit operating income growth, with strong renewals and pipeline supporting new wins and World Courier regaining momentum after fiscal '25 challenges.
"In our European business, it continued to benefit from the timing of manufacturer price increases, in developing market country, consistent with previous quarters." — Eva Boratto (CFO)
340B exposure and value to participants
Q (Eric Percher · Nephron): Analyst asked about Cencora's focus in 340B (covered entities vs TPAs/contract pharmacy), what they are doing in 340B, and their value proposition to participants.
A: Management said they have a broad portfolio of customers and if changes are implemented there would be different impacts to different parts of the business, not necessarily all negative. They said they are still assessing potential changes and would not size impacts until something is implemented.
"And so if something were to go through and be implemented there would be different impacts to different parts of the business, which we haven't really spoken to." — Robert Mauch (CEO)
Customer mix and contract renewals
Q (Michael Cherny · Leerink): Analyst asked if the current customer mix is where management wants it to be, and whether there are any significant renewals or unusual moves happening with large customers.
A: Management said they are happy with a broad customer portfolio across sites of care and their goal is to support patient access by ensuring customers have product at the right time and price. They said relationships with both large and small customers are good and there is nothing to call out on renewals.
"Our relationships with our large customers and our small customers are good and nothing to call out in terms of renewals." — Robert Mauch (CEO)